Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study

PURPOSE: This phase Ib study defined the safety, MTD, and recommended phase II dose (RP2D) of regorafenib combined with vincristine and irinotecan (VI). Secondary objectives were evaluation of antitumor activity and pharmacokinetics (PK) of regorafenib and irinotecan. PATIENTS AND METHODS: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Casanova, Michela, Bautista, Francisco, Campbell-Hewson, Quentin, Makin, Guy, Marshall, Lynley V., Verschuur, Arnauld C., Cañete Nieto, Adela, Corradini, Nadège, Ploeger, Bart A., Brennan, Barbara J., Mueller, Udo, Zebger-Gong, Hong, Chung, John W., Geoerger, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618645/
https://www.ncbi.nlm.nih.gov/pubmed/37606641
http://dx.doi.org/10.1158/1078-0432.CCR-23-0257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618645/
https://www.ncbi.nlm.nih.gov/pubmed/37606641
http://dx.doi.org/10.1158/1078-0432.CCR-23-0257

Ejemplares similares